Henoch-Schönlein purpura – State-of-the-Art Diagnosis and Treatment
Authors:
S. Skálová 1; J. Zieg 2; L. Minxová 1
Authors place of work:
Dětská klinika LF UK a FN, Hradec Králové
přednosta prof. MUDr. M. Bayer, CSc.
1; Pediatrická klinika UK 2. LF a FN Motol, Praha
přednosta prof. MUDr. J. Lebl, CSc.
2
Published in the journal:
Čes-slov Pediat 2010; 65 (11): 660-666.
Category:
Postgraduate Education
Summary
Henoch-Schönlein purpura (HSP) is one of the most common vasculitides of childhood. The diagnosis is based on the clinical symptomatology that includes a typical pattern of palpable cutaneous purpura, joint involvement, renal and gastrointestinal symptoms, and less often also involvement of other organs. From the point of view of the treatment, corticosteroids have proven effective in reducing the duration and severity of gastrointestinal and joint symptoms, but not adequately effective in the prevention and treatment of nephritis. Uniform guidelines for the treatment of HSP and HSP nephritis have not been available yet. Based on the gained experience, renin-angiotensin system inhibitors, fish oil, immunosuppressants, plasmapheresis and tonsillectomy are used in the treatment of HSP nephritis.
Key words:
Henoch-Schönlein purpura, vasculitis, nephritis, corticosteroids, immunosuppressants
Zdroje
1. Gardner-Medwin JM, Dolezalova P, Cummins C, et al. Incidence of Henoch-Schönlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet 2002 Oct 19; 360: 1197–202.
2. Henoch EH. Uber ein eigenthe Form von Purpura. Berl. Klin. Wochenschr. 1974; 11:641–643.
3. Brogan PA. What’s new in the aetiopathogenesis of vasculitis? Pediatr. Nephrol. 2007; 22: 1083–1094.
4. Lau KK, Suzuki H, Novak J, et al. Pathogenesis of Henoch-Schönlein purpura nephritis. Pediatr. Nephrol. 2010; 25: 19–26.
5. Matoušovic K, Mestecký J, Tomana M, et al. Imunoglobulin A a choroby ledvin. Vnitř. Lék. 2006; 52: 256–262.
6. Saulsbury FT. Henoch-Schönlein purpura. Curr. Opin. Rheumatol. 2001; 13: 35–40.
7. Soylemezoglu O, Peru H, Gonen S, et al. HLA-DRB1 alleles and Henoch-Schönlein purpura: susceptibility and severity of disease. J. Rheumatol. 2008; 35: 1165–1168.
8. Amoli MM, Thomson W, Hajeer AH, et al. HLA-B35 association with nephritis in Henoch-Schönlein purpura. J. Rheumatol. 2002; 29: 948–949.
9. Ozdogan H, Arisoy N, Kasapçapur O, et al. Vasculitis in familial Mediterranean fever. J. Rheumatol. 1997; 24: 323–327.
10. Saulsbury FT. Successful treatment of prolonged Henoch-Schönlein purpura with kolchicine. Clin. Pediatr. 2009; 48: 866–868.
11. Ozen S, Pistorio A, Iusan SM, et al. EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arthritis: Ankara 2008. Part II: Final classification criteria. Ann. Rheum. Dis. 2010; 69: 798–806.
12. Al-Sheyab M, El-Shanti H, Ajlouni S, et al. The clinical spectrum of Henoch-Schönlein purpura in infants and young children. Eur. J. Pediatr. 1995; 154: 969–972.
13. McCarthy HJ, Tizard EJ. Clinical practice: Diagnosis and management of Henoch-Schönlein purpura. Eur. J. Pediatr. 2009; 169: 643–650.
14. Narchi H. Risk of long-term renal impairment and duration of follow up recommended for Henoch- -Schönlein purpura with normal or minimal urinary findings: a systematic review. Arch. Dis. Child. 2005; 90: 921–924.
15. Bogdanović R. Henoch-Schönlein purpura nephritis in children: risk factors, prevention and treatment. Acta Pediatr. 2009; 98: 1882–1889.
16. Kaku Y, Yonekawa Y, Taub E. Renal involvement in Henoch-Schönlein purpura: a multivariate analysis of prognostic factors. Kidney Int. 1998; 53: 1755–1759.
17. Halling SE, Söderberg MP, Berg UB. Predictors of outcome in Henoch-Schönlein nephritis. Pediatr. Nephrol. 2010; 25: 1101–1108.
18. Rieu P, Noël LH. Henoch-Schönlein nephritis in children and adults. Morphological features and clinicopathological correlations. Ann. Med. Interne (Paris) 1999; 150: 151–159.
19. Zieg J, Skálová S. Postižení ledvin při Henoch- -Schönleinově purpuře. Pediatrie pro Praxi 2010; 11: 169–171.
20. Butani L, Morgenstern BZ. Long-term outcome in children after Henoch-Schönlein purpura nephritis. Clin. Pediatr. 2007; 46: 505–511.
21. Ronkainen J, Koskimies O, Ala-Houhala M, et al. Early prednisone therapy in Henoch-Schönlein purpura: a randomized, double-blind, placebo-controlled trial. J. Pediatr. 2006 Aug; 149: 241–247.
22. Sohagia AB, Gunturu SG, Tong TR, et al. Henoch-Schoenlein purpura – A case report and review of the literature. Gastroenterol. Res. Pract. 2010; 2010:597648. Epub 2010 May 23.
23. Buchanec J, Galanda V, Belakova S, et al. Incidence of renal complications in Schoenlein-Henoch purpura syndrome in dependence of an early administration of steroids. Int. Urol. Nephrol. 1998; 20: 409–412.
24. Weis PF, Klink AJ, Hexem K, et al. Variation in inpatient therapy and diagnostic evaluation of children with Henoch-Schönlein purpura. J. Pediatr. 2009; 155: 801–806.
25. Edström Halling S, Söderberg MP, Berg UB. Treatment of severe Henoch-Schönlein and immunoglobulin A nephritis. A single center experience. Pediatr. Nephrol. 2009; 24: 91–97.
26. Dixit MP, Dixit NM, Scott K. Managing Henoch--Schönlein purpura in children with fish oil and ACE inhibitor therapy. Nephrology 2004; 9: 381–386.
27. Inoue CN, Chiba Y, Morimoto T, et al. Tonsillectomy in the treatment of pediatric Henoch-Schönlein nephritis. Clin. Nephrol. 2007; 67: 298–305.
28. Niaudet P, Habib R. Methylprednisolone pulse therapy in the treatment of severe forms of Schönlein-Henoch purpura nephritis. Pediatr. Nephrol. 1998; 12: 238–243.
29. Foster BJ, Bernard C, Drummond KN, et al. Effective therapy for severe Henoch-Schönlein purpura nephritis with prednisone and azathioprine: a clinical and histopathologic study. J. Pediatr. 2000; 136: 370–375.
30. Tanaka H, Suzuki K, Nakahata T, et al. Early treatment with oral immunosuppressants in severe proteinuric purpura nephritis. Pediatr. Nephrol. 2003; 18: 347–350.
31. Tarshish P, Bernstein J, Edelmann CM. Henoch-Schönlein purpura nephritis: course of disease and efficacy of cyclophosphamide. Pediatr. Nephrol. 2004; 19: 51–56.
32. Shin JI, Park JM, Lee JS, et al. Successful use of cyclosporin A in severe Schönlein-Henoch nephritis resistant to both methylprednisolone pulse and azathioprine. Clin. Rheumatol. 2006; 25: 759–760.
33. Shenoy M, Ognjanovic MV, Coulthard MG. Treating severe Henoch-Schönlein and IgA nephritis with plasmapheresis alone. Pediatr. Nephrol. 2007; 22: 1167–1171.
34. Buchanec J, Zibolen M, Hyrdelová E, et al. Možná prevencia vzniku nefropatie pri Schoenlein-Henochovej purpure včasným podaním prednisonu – dôvody pre a proti. Čes.-slov. Pediat. 1998; 53: 256–259.
35. Jeseňák M, Antonová M, Brndiarová M, et al. Henochova-Schönleinova purpura z pohľadu preventivného podávania kortikoidov. Čes.-slov. Pediat. 2008; 63: 557–564.
36. Zaffanello M, Fanos V. Treatment-based literature of Henoch-Schönlein purpura nephritis in childhood. Pediatr. Nephrol. 2009; 24: 1901–1911.
37. Chartapisak W, Opastriakul S, Willis NS, et al. Prevention and treatment of renal diseases in Henoch-Schönlein purpura: a systematic review. Arch. Dis. Child. 2009; 94: 132–137.
Štítky
Neonatology Paediatrics General practitioner for children and adolescentsČlánok vyšiel v časopise
Czech-Slovak Pediatrics
2010 Číslo 11
- What Effect Can Be Expected from Limosilactobacillus reuteri in Mucositis and Peri-Implantitis?
- The Importance of Limosilactobacillus reuteri in Administration to Diabetics with Gingivitis
Najčítanejšie v tomto čísle
- Henoch-Schönlein purpura – State-of-the-Art Diagnosis and Treatment
-
Hemolytic Uremic Syndrome (HUS) – One of the Most Common Causes of Acute Renal Failure in Childhood.
Complexity of the Pathophysiology and Novel Diagnostic and Therapeutic Options for Atypical Forms - Current Trends in the Treatment of Invagination in Childhood
- Imunoglukan P4H® in the Prevention of Recurrent Respiratory Infections in Childhood